Anthracycline dose in childhood acute lymphoblastic leukemia: Issues of early survival versus late cardiotoxicity

Journal of Clinical Oncology

Volumn 15, Issue 1, 1997, Pages 61-68

  Sorensen, K ^a   Levitt, G ^a   Bull, C ^a   Chessells, J ^a   Sullivan, I ^a  

^a GREAT ORMOND STREET HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ARTICLE; CANCER SURVIVAL; CARDIOTOXICITY; CHILD; DOSE CALCULATION; DRUG SAFETY; FEMALE; HEART FUNCTION; HEART LEFT VENTRICLE PERFORMANCE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0031017043     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1997.15.1.61     Document Type: Article

References (21)

1. Von Hoff DD, Rozencweig M, Layard M, et al: Daunomycin-induced cardiotoxicity in children and adults. Am J Med 62:200-208, 1977
2. Goorin AM, Chauvenet AR, Perez-Atayde AR, et al: Initial congestive heart failure six to ten years after doxorubicin chemotherapy for childhood cancer. J Pediatr 116:144-147, 1990
3. Lipshultz SE, Colan SD, Gelber ED, et al: Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in children. N Engl J Med 324:808-815, 1991
4. Eden OB, Lilleyman JS, Richards S, et al: Results of Medical Research Council childhood leukaemia trial UKALL VIII (Report to the Medical Research Council on behalf of the Working Party on Leukaemia in Childhood). Br J Haematol 78:187-196, 1991
5. Chessells JM, Bailey C, Richards SM: Intensification of treatment and survival in all children with lymphoblastic leukaemia: Results of UK Medical Research Council trial UKALL X. Lancet 345:143-148, 1995
6. Pinkerton CR, Bowman A, Holtzel H, et al: Intensive consolidation chemotherapy for acute lymphoblastic leukaemia (UKALL X pilot study). Arch Dis Child 62:12-18, 1987
7. Iwahara M, Benson LN, Freedom RM: Noninvasive estimation of end-systolic aortic pressure in children. Echocardiography 8:559-562, 1991
8. Colan SM, Borow KM, Neumann A: The left ventricular end-systolic wall stress velocity of fibre shortening relation: A load independent index of myocardial contractility. J Am Coll Cardiol 4:715-724, 1984
9. Grossman W, Jones D, McLaurin LP: Wall stress and pattern of hypertrophy in the human left ventricle. J Clin Invest 56:56-64, 1975
10. Colan SD, Parness IA, Spevak PJ, et al: Developmental modulation of myocardial mechanics: Age- and growth-related alterations in afterload and contractility. J Am Coll Cardiol 19:619-629, 1992
11. Lipshultz SE, Lipsitz SR, Mone SM: Female sex and higher drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med 332:1738-1743, 1995
12. Steinherz LJ, Steinherz PG, Tan CJ, et al: Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA 266:1672-1677, 1991
13. Hausdorf G, Morf G, Beron G, et al: Long term doxorubicin cardiotoxicity in childhood: Non-invasive evaluation of the contractile state and diastolic filling. Br Heart J 60:309-315, 1988
14. Bu'Lock FA, Mott MG, Oakhill A, et al: Left ventricular diastolic function after anthracycline chemotherapy in childhood: Relation with systolic function, symptoms, and pathophysiology. Br Heart J 73:340-350, 1995
15. Leandro J, Dyck J, Poppe D, et al: Cardiac dysfunction late after cardiotoxic therapy for childhood cancer. Am J Cardiol 74:1152-1156, 1994
16. Uruena M, Stanhope R, Chessells JM, et al: Impaired pubertal arowth in acute lymphoblastic leukaemia. Arch Dis Child 66:1403-1407, 1991
17. Clavell LA, Gelber RD, Cohen HJ, et al: Four-agent induction and intensive asparaginase therapy for treatment of childhood acute lymphoblastic leukemia. N Engl J Med 315:657-663, 1986
18. Niermeyer CM, Hitchcock-Bryan S, Sallan SE: Comparative analysis of treatment programs for childhood acute lymphoblastic leukemia. Semin Oncol 12:122-130, 1995
19. Steinherz LJ, Graham T, Hurwitz R, et al: Guidelines for cardiac monitoring of children during and after anthracycline therapy: Report of the Cardiology Committee of the Children's Cancer Study Group. Pediatrics 89:942-949, 1992
20. Lipshultz SE, Sanders SP, Goorin AN, et al: Monitoring for anthracycline cardiotoxicity. Pediatrics 93:433-437, 1994
21. Sorensen K, Levitt G, Sebag-Montefiore D, et al: Cardiac function in Wilms' tumor survivors. J Clin Oncol 13:1546-1556, 1995